LaserSight's LaserScan LSX Will Be Sold By Six U.S. Direct Sales Reps
This article was originally published in The Gray Sheet
Executive Summary
LaserSight will seek approval of its LaserScan LSX laser assisted in situ keratomileusis (LASIK) system for correction of farsightedness (hyperopia).
You may also be interested in...
LaserSight Excimer Laser Sales On Hold Pending Visx License Negotiations
LaserSight says it will delay marketing of the LaserScan LSX ophthalmic excimer laser system in the U.S. while it negotiates a license agreement with competitor Visx.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”